Cabotegravir plus Rilpivirine for Persons with HIV and Adherence Challenges

Key Points

• This research aims to evaluate the efficacy of cabotegravir and rilpivirine in persons living with HIV who face adherence challenges.
• Randomized trial design to compare treatment outcomes.
• Included persons with HIV experiencing difficulties in adhering to medication.
• Analyzed changes in viral load and adherence rates post-treatment.
• Cabotegravir plus rilpivirine decreased viral load significantly with an 85% reduction (p<0.001).
• Adherence rates improved by over 70% in the intervention group compared to standard care.
• Indicated a strong preference among participants for the combined treatment approach.